11 Osteogenesis Imperfecta Clinical Trials in Milwaukee, WI (2026)

Q: How do I join a clinical trial in Milwaukee?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Milwaukee research site will contact you.

Recruiting Osteogenesis Imperfecta Studies in Milwaukee

NCT07631598Recruiting

Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses

This study is testing whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay in treatment for opioid use disorder (OUD) than referring th...

Milwaukee, WINA512 participantsMontefiore Medical Center

View Study Details

NCT04771130Recruiting

A Study of BGB-11417 in Participants With Myeloid Malignancies

The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute m...

Milwaukee, WIPHASE1260 participantsBeiGene

View Study Details

NCT06863207Recruiting

Autonomic Reactivity and Personalized Neurostimulation

Disorders of gut-brain interaction (DGBI) affect up to 25% of U.S. children. Patients often suffer from disabling, multisystem comorbidities that suggest a common root (sleep disturbances, fatigue, an...

Milwaukee, WINA120 participantsMedical College of Wisconsin

View Study Details

NCT04892823Recruiting

Social Relationships and Accelerated Aging in Hematopoietic Cell Transplant Survivors

This project aims to elucidate the important protective elements of social relationships and identify concrete, modifiable behavioral factors that contribute to biological and phenotypic aging in hema...

Milwaukee, WI110 participantsMedical College of Wisconsin

View Study Details

NCT06680037Recruiting

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel)....

Milwaukee, WIPHASE1100 participantsTG Therapeutics, Inc.

View Study Details

NCT05212129Recruiting

Auricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome

Hypermobile Ehlers-Danlos Syndrome (hEDS) is a connective tissue disorder characterized by hyperextensible skin, joint hypermobility and additional connective tissue manifestations. For unclear reason...

Milwaukee, WINA90 participantsMedical College of Wisconsin

View Study Details

NCT06158854Recruiting

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis has many root causes and is characterized by the overproduction of AL that are secreted by c...

Milwaukee, WIPHASE176 participantsAbbVie

View Study Details

NCT06707493Recruiting

Ivosidenib as Post-HSCT Maintenance for AML

This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell tran...

Milwaukee, WIPHASE275 participantsMassachusetts General Hospital

View Study Details

NCT04838041Recruiting

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

This is a single arm phase II study that will enroll a minimum of 47 subjects with a maximum of 51. All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have...

Milwaukee, WIPHASE251 participantsMedical College of Wisconsin

View Study Details

NCT05317403Recruiting

Venetoclax to Augment Epigenetic Modification and Chemotherapy

The investigator is testing the addition of venetoclax to 5-azacitidine and vorinostat followed by standard chemotherapy to enhance treatment response in AML patients....

Milwaukee, WIPHASE140 participantsMedical College of Wisconsin

View Study Details

NCT07110844Recruiting

Teclistamab-Daratumumab in AL Amyloidosis

The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis. The study treatment is divided into cycles (C) and each cycle is 28 da...

Milwaukee, WIPHASE225 participantsSuzanne Lentzsch, MD

View Study Details

About Osteogenesis Imperfecta Clinical Trials in Milwaukee

Osteogenesis imperfecta is a group of genetic disorders mainly affecting the bones, causing them to break easily, often from little or no apparent cause. It is caused by defects in collagen production. Treatment includes bisphosphonates, physical therapy, and surgical rodding.

There are currently 11 osteogenesis imperfecta clinical trials recruiting participants in Milwaukee, WI. These studies are seeking a combined 1,459 participants. Research is being sponsored by Montefiore Medical Center, BeiGene, Medical College of Wisconsin and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Osteogenesis Imperfecta Clinical Trials in Milwaukee — FAQ

Are there osteogenesis imperfecta clinical trials in Milwaukee?

Yes, there are 11 osteogenesis imperfecta clinical trials currently recruiting in Milwaukee, WI. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Milwaukee?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Milwaukee research site will contact you about next steps.

Are clinical trials in Milwaukee free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Milwaukee studies also compensate for your time and travel.

What osteogenesis imperfecta treatments are being tested?

The 11 active trials in Milwaukee are testing new therapies including novel drugs, biologics, and treatment approaches for osteogenesis imperfecta.

Data updated October 17, 2026 from ClinicalTrials.gov